MDR_Button Contact_Button News_Button  
Column Header 1 Column Header 2 Column Header 3
 
CBA Pharma, Inc. is organized to exclusively manufacture, market, license and distribute to the medical oncology community a drug, CBT-1®, developed to be an effective treatment for cancer that has developed or may develop drug resistance to chemotherapy.
CBT-1®, taken orally as a pill, was developed to reverse multi-drug resistance in cancer cells and to become part of a Cancer Treatment Program that is administered before a cancer cell can become drug resistant.
(MDR) is the phenomenon whereby cells become resistant to a variety of chemotherapy drugs. Resistance of cancer cells to chemotherapy remains the major cause of treatment failure.
 
© CBA Pharma, Inc. 2014 All Rights Reserved Contact Us Privacy Statement Terms and Conditions